Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

November 30, 2019

Study Completion Date

April 30, 2020

Conditions
Adenocarcinoma of the Prostate
Interventions
OTHER

Active CTC Assessment

CTC Counts used to guide treatment switch

Trial Locations (4)

SM2 5PT

The Royal Marsden Hospital, Sutton

Unknown

Velindre Cancer Centre, Cardiff

Western General Hospital, Edinburgh

University College London Hospital, London

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Prostate Cancer UK

OTHER

collaborator

University of Twente

OTHER

collaborator

Sanofi

INDUSTRY

collaborator

Janssen, LP

INDUSTRY

collaborator

Menarini Group

INDUSTRY

lead

Institute of Cancer Research, United Kingdom

OTHER